Shares of Spero Therapeutics (NASDAQ:SPRO) climbed 16% on Thursday after the FDA approved Utebzi, an oral carbapenem antibiotic jointly developed by GlaxoSmithKline (NYSE:GSK) and Spero. The approval covers the treatment of complicated urinary tract infections, including pyelonephritis, in adult patients who have limited or no alternative oral treatment options.
Utebzi is the first and only oral carbapenem to receive approval in the United States. The regulatory decision follows GSK's development work and an exclusive global licensing arrangement with Spero, with an exception for certain Asian territories specified in that agreement.
Complicated urinary tract infections represent a substantial clinical burden in the U.S., with more than 3 million cases occurring each year. Treatment failure can be common, affecting as many as 34% of patients, and these infections - often driven by multidrug-resistant organisms - are associated with more than $6 billion in annual healthcare spending.
Carbapenems have been the standard of care for severe or resistant infections, but until now their use has been constrained to intravenous administration. Utebzi provides an oral option for a class of antibiotics that previously required hospital-based IV delivery.
The FDA decision was based on data from the PIVOT-PO phase III clinical trial. That study evaluated tebipenem pivoxil against intravenous imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including pyelonephritis. In the trial, tebipenem pivoxil produced an overall success rate of 58.5% (261 out of 446 participants), compared with a 60.2% success rate for imipenem-cilastatin (291 out of 483 participants). The adjusted treatment difference was -1.3%, with a 95% confidence interval from -7.5% to 4.8%, meeting the study's non-inferiority criteria.
Safety data for tebipenem pivoxil were generally comparable to those observed with imipenem-cilastatin and other carbapenem antibiotics. The most commonly reported adverse events were diarrhea and headache; these events were described as mild or moderate in severity and non-serious.
Utebzi is expected to become available to patients in the United States by the end of 2026. The development program for tebipenem pivoxil received partial federal support through funding from the U.S. Department of Health and Human Services via the Biomedical Advanced Research and Development Authority (BARDA).
Market reaction and context
The FDA approval prompted an immediate equity market response for Spero Therapeutics, reflecting investor recognition of the regulatory milestone and the potential clinical role for an oral carbapenem. The collaboration with GSK underpins the global development and commercialization pathway, subject to the territorial exceptions noted in their agreement.
Key points
- FDA approved Utebzi (tebipenem pivoxil) for complicated UTIs, including pyelonephritis, in adults with limited or no alternative oral options.
- Utebzi is the first oral carbapenem authorized in the U.S., based on PIVOT-PO phase III data showing non-inferiority to IV imipenem-cilastatin.
- The approval has implications for healthcare and pharmaceutical markets, particularly in the treatment of multidrug-resistant urinary infections and hospital-to-outpatient care conversion.
Risks and uncertainties
- The PIVOT-PO trial reported an overall success rate for tebipenem pivoxil that was slightly lower than imipenem-cilastatin (58.5% versus 60.2%), with an adjusted treatment difference of -1.3% and a confidence interval that spans both negative and positive values, indicating uncertainty around the magnitude of effect.
- Although adverse events were generally mild or moderate, safety monitoring will remain important as use expands beyond the clinical trial setting.
- Utebzi's availability is projected by the end of 2026, meaning patients and payers will not have immediate access and commercial rollout timing could affect uptake and market dynamics.
Conclusion
The FDA approval of Utebzi marks a regulatory and therapeutic milestone by introducing an oral carbapenem option for adults with complicated urinary tract infections when oral alternatives are unavailable. The decision is grounded in phase III evidence of non-inferiority to an established intravenous carbapenem and accompanied by a safety profile similar to other agents in the class. Spero Therapeutics' stock reacted positively to the news, and the product is slated for U.S. availability by the end of 2026, with part of its development funded through BARDA.